Royal College of Paediatrics and Child Health
Leading the way in Children's Health

Clinical Standards
5-11 Theobalds Road, London WC1X 8SH
Tel: 020 7092 6160 | Fax: 020 7092 6001
clinical.standards@rcpch.ac.uk

NICE Eculizumab for the treatment of atypical haemolytic uraemic syndrome

Evaluation Consultation Document

Name	Royal College of Paediatrics and Child Health Comments on behalf of the following: [redacted]
Contact details	Clinical.standards@rcpch.ac.uk
Questions to consider	**Comments**
Has all of the relevant evidence been taken into account?	Yes, although it is not clear from the evidence whether medium term treatment (withdrawing eculizumab in stable patients, which would reduce costs) could be considered.
Are the summaries of clinical effectiveness and value for money reasonable interpretations of the evidence?	Yes.
Are the provisional recommendations sound and a suitable basis for guidance to NHS England?	Yes, although the cost- benefit equation is obviously of little consequence to patients who see a such dramatic improvement in QoL with eculizumab.